EPS for Matinas BioPharma Holdings, Inc. (MTNB) Expected At $-0.03

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) Logo

Analysts expect Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) to report $-0.03 EPS on May, 9.They anticipate $0.02 EPS change or 40.00 % from last quarter’s $-0.05 EPS. After having $-0.03 EPS previously, Matinas BioPharma Holdings, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 1.92% or $0.02 during the last trading session, reaching $1.02. About 493,246 shares traded. Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) has risen 27.72% since May 8, 2018 and is uptrending. It has outperformed by 23.35% the S&P500.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company has market cap of $145.80 million. The firm develops orally delivered therapeutics based on a proprietary, lipid drug delivery platform called cochleate delivery technology. It currently has negative earnings. The Company’s lead product candidate is MAT 2203, an orally-administered cochleate formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections.

Another recent and important Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) news was published by Seekingalpha.com which published an article titled: “Matinas BioPharma Holdings, Inc. 10-K Apr. 1, 2019 4:53 PM – Seeking Alpha” on April 01, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.